CA2703054C - Hydrated crystalline esters of camptothecin for the treatment of cancer - Google Patents

Hydrated crystalline esters of camptothecin for the treatment of cancer Download PDF

Info

Publication number
CA2703054C
CA2703054C CA2703054A CA2703054A CA2703054C CA 2703054 C CA2703054 C CA 2703054C CA 2703054 A CA2703054 A CA 2703054A CA 2703054 A CA2703054 A CA 2703054A CA 2703054 C CA2703054 C CA 2703054C
Authority
CA
Canada
Prior art keywords
cancer
crystalline
camptothecin
hydrate
crystalline camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2703054A
Other languages
English (en)
French (fr)
Other versions
CA2703054A1 (en
Inventor
Zhisong Cao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cao Pharmaceuticals Inc
Original Assignee
Cao Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cao Pharmaceuticals Inc filed Critical Cao Pharmaceuticals Inc
Publication of CA2703054A1 publication Critical patent/CA2703054A1/en
Application granted granted Critical
Publication of CA2703054C publication Critical patent/CA2703054C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2703054A 2007-10-25 2008-10-24 Hydrated crystalline esters of camptothecin for the treatment of cancer Active CA2703054C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/923,727 2007-10-25
US11/923,727 US7572803B2 (en) 2007-10-25 2007-10-25 Hydrated crystalline esters of camptothecin
PCT/US2008/081047 WO2009055633A1 (en) 2007-10-25 2008-10-24 Hydrated crystalline esters of camptothecin for the treatment of cancer

Publications (2)

Publication Number Publication Date
CA2703054A1 CA2703054A1 (en) 2009-04-30
CA2703054C true CA2703054C (en) 2017-08-22

Family

ID=40229972

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2703054A Active CA2703054C (en) 2007-10-25 2008-10-24 Hydrated crystalline esters of camptothecin for the treatment of cancer

Country Status (11)

Country Link
US (1) US7572803B2 (https=)
EP (1) EP2205605B1 (https=)
JP (1) JP5487111B2 (https=)
KR (1) KR20100082358A (https=)
CN (1) CN101730701B (https=)
BR (1) BRPI0816584A2 (https=)
CA (1) CA2703054C (https=)
ES (1) ES2396222T3 (https=)
MX (1) MX2010004332A (https=)
RU (1) RU2483071C2 (https=)
WO (1) WO2009055633A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130121921A1 (en) 2011-11-11 2013-05-16 The Christus Stehlin Foundation For Cancer Research Rodent Therapeutic Model And Methods
US9387257B2 (en) * 2014-01-17 2016-07-12 Academia Sinica Lung cancer specific peptides for targeted drug delivery and molecular imaging
US9675609B2 (en) * 2015-11-11 2017-06-13 Cao Pharmaceuticals Inc. Nano- and micro-sized particles of 20-camptothecin or derivative thereof and pharmaceutical compositions containing same, and treatment of cancers therewith
TW202128189A (zh) * 2019-11-20 2021-08-01 美商威瓦西塔腫瘤公司 使用喜樹鹼衍生物之癌症治療

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5352789A (en) * 1993-02-25 1994-10-04 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5527913A (en) * 1993-02-25 1996-06-18 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6407118B1 (en) * 1996-01-30 2002-06-18 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US5731316A (en) * 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US5922877A (en) * 1997-08-05 1999-07-13 The Stehlin Foundation For Cancer Research Methods of preparing and purifying 9-nitro-20-camptothecin
USRE38408E1 (en) * 1997-08-05 2004-01-27 The Stehlin Foundation For Cancer Research Methods of preparing and purifying 9-nitro-20-camptothecin
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) * 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6699875B2 (en) * 2002-05-06 2004-03-02 The Stehlin Foundation For Cancer Research Cascade esters of camptothecins and methods of treating cancer using these compounds
US6703399B2 (en) * 2002-05-06 2004-03-09 The Stehlin Foundation For Cancer Research Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds
NZ541990A (en) * 2003-02-25 2009-04-30 Yakult Honsha Kk Method for preparing polymorphism of irinotecan hydrochloride
TWI333492B (en) * 2003-11-12 2010-11-21 Smithkline Beecham Cork Ltd Crystalline topotecan hydrochloride product and preparation thereof
EP2082741A1 (en) * 2005-09-20 2009-07-29 Scinopharm Singapore Pte, Ltd. Novel crystal form of irinotecan hydrochloride

Also Published As

Publication number Publication date
RU2010120810A (ru) 2011-11-27
KR20100082358A (ko) 2010-07-16
CN101730701A (zh) 2010-06-09
US7572803B2 (en) 2009-08-11
EP2205605A1 (en) 2010-07-14
CN101730701B (zh) 2013-05-29
US20090111845A1 (en) 2009-04-30
CA2703054A1 (en) 2009-04-30
RU2483071C2 (ru) 2013-05-27
JP2011500841A (ja) 2011-01-06
WO2009055633A1 (en) 2009-04-30
ES2396222T3 (es) 2013-02-20
BRPI0816584A2 (pt) 2015-03-03
MX2010004332A (es) 2010-05-20
JP5487111B2 (ja) 2014-05-07
EP2205605B1 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
US6352996B1 (en) Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US5916896A (en) Water-soluble esters of camptothecin compounds
US6096336A (en) Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
CN100406013C (zh) 喜树碱衍生物
AU2002243367A1 (en) Camptothecin derivatives
CA2703054C (en) Hydrated crystalline esters of camptothecin for the treatment of cancer
AU2007224896B2 (en) Camptothecin derivatives and their use
US6699875B2 (en) Cascade esters of camptothecins and methods of treating cancer using these compounds
CA2484816C (en) Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds
US20040034050A1 (en) Homo-camptothecin derivatives
CN108586535A (zh) 含喜树碱结构的磷脂类似物、制备方法及用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131024

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250424